Table. Immune-Mediated Toxic Effects Possibly Related to Ipilimumab for Run-in Phase 1 and Phase 2.
| Adverse Event | Patients, No. (%) | |
|---|---|---|
| All Grades | Grade ≥3 | |
| Diarrhea | 12 (29) | 4 (33) |
| Colitis | 2 (5) | 1 (50) |
| Enterocolitis | 1 (2) | 1 (100) |
| Pancolitis | 1 (2) | 1 (100) |
| Colonic perforation | 1 (2) | 1 (100) |
| Maculopapular rash | 12 (29) | 1 (8) |
| Pruritus | 9 (21) | 1 (11) |
| Increased aspartate aminotransferase | 9 (21) | 1 (11) |
| Increased alanine aminotransferase | 9 (21) | 0 |
| Arthralgia | 3 (7) | 1 (33) |
| Peripheral neuropathy | 2 (5) | 0 |
| Hypothyroidism | 2 (5) | 0 |